Ortho Clinical Diagnostics (OCDX) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Ortho Clinical Diagnostics Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2021
January 6, 2022 4:50 PM ESTExpects 4Q Reported and Constant Currency Core Revenue Growth of ~4%Fiscal Year Reported and Constant Currency Core Revenue Growth of ~16% and ~15%, respectively
RARITAN, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the Company), one of the worlds largest pure-play in vitro diagnostics (IVD) companies, today announced preliminary unaudited revenue results for the fourth quarter and fiscal year ended January 2, 2022. The Company is providing these updates in advance of its presentation at the J.P. Morgan Healthcare Conference on January 11, 2022.
... More